C4 Therapeutics, Inc. announced the appointment of Owen Hughes to its board of directors. Mr. Hughes is an accomplished life sciences executive with nearly three decades of experience in investing, operations and corporate governance. Mr. Hughes most recently served as co-founder and chief executive officer of Cullinan Oncology, where he led the development of the company?s portfolio of oncology assets through proof-of-concept.

Under Mr. Hughes?s leadership, Cullinan raised over $400 million in capital through its initial public offering and advanced several assets into the clinic. Mr. Hughes also served as chief business officer of Intarcia Therapeutics, where he raised over $1.4 billion in capital and completed several portfolio deals totaling more than $1 billion. Mr. Hughes started his career on Wall Street, initially in investment banking and equity research before transitioning to the buyside, where he managed public and private healthcare investments for Brookside Capital, a hedge fund under the Bain Capital umbrella, and Pyramis Advisors, a Fidelity Investments company.

Mr. Hughes currently serves as the executive chairman of Sail Bio and XOMA Corporation as well as the chairman of Ikena Oncology. He previously served on the boards of Radius Health (acquired by Gurnet Point Capital) and Translate Bio (acquired by Sanofi). Mr. Hughes earned a B.A. in history from Dartmouth College.